Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Alzheimer Disease peripheral blood mononuclear cell expression

ABSTRACT: Comparisons between the sample groups (normal elderly control (NEC) and Alzheimer disease (AD)) allow the identification of genes with disease and gender expression patterns. Keywords: biological repeat

ORGANISM(S): Homo sapiens

PROVIDER: GSE4226 | GEO | 2006/10/13

SECONDARY ACCESSION(S): PRJNA94873

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

GSTM3 single nucleotide polymorphism (rs7483) associated with peripheral BMC expression in Alzheimer disease

Project description:Comparisons between the sample groups (normal elderly control (NEC) and Alzheimer disease (AD)) allowed the identification of genes with disease expression patterns associated with the glutathione S-transferase M3 single nucleotide polymorphism rs7483. Keywords: biological repeat Peripheral blood mononuclear cells (BMC) were obtained from normal elderly control (NEC) and Alzheimer disease (AD) subjects. Targets from biological replicates of NEC (n=18) and AD (n=16) were generated and the expression profiles were determined using the NIA Human MGC cDNA microarray.

2010-06-24 | E-GEOD-4227 | biostudies-arrayexpress

GSTM3 single nucleotide polymorphism (rs7483) associated with peripheral BMC expression in Alzheimer disease

2009-01-12 | GSE4227 | GEO

Alzheimer, MCI and control samples from AddneuroMed Cohort (batch 1)

Project description:Alzheimer case-control samples originate from the EU funded AddNeuroMed Cohort, which is a large cross-European AD biomarker study relying on human blood as the source of RNA. The design is case-control. Cases are either Alzheimer's disease patients, subjects with mild cognitive impairment or age and gender matched controls.

2015-08-05 | E-GEOD-63060 | biostudies-arrayexpress

Alzheimer disease diagnostic prediction using peripheral BMC gene expression

Project description:Using prediction analysis for microarrays (PAM), peripheral blood mononuclear cells (BMC) gene expression proves useful as predictive markers of sporadic AD. We obtained 90% accuracy for correct AD classification by PAM (36 of 40; four NEC classified as AD) using BMC gene expression. Investigating the contribution of these genes to the pathology of AD and their usefulness as prognostic biomarkers holds promise in the prevention of this devastating disease.

2009-01-12 | GSE4229 | GEO

Alzheimer, Mild Cognitive impairment and control samples from AddneuroMed Cohort (batch 2)

2015-08-05 | E-GEOD-63061 | biostudies-arrayexpress

Transcriptomes in Peripheral Blood Mononuclear Cells of Dementia and Alzheimer Patients

Project description:With the aging population, there is a growing focus on dementia, especially Alzheimer’s disease (AD). The molecular basis underlying the pathogenesis of AD is gradually being elucidated. Increasing evidence has shown that the immunological function of leukocytes plays a crucial role in the development of neurodegenerative disorders. However, there have been few studies among the Taiwanese population. The aim of this study was to investigate potential biomarkers for early diagnosis of Alzheimer’s disease from blood leukocytes.

2009-11-30 | GSE18309 | GEO

RNA-seq of human plasma microRNAs in Alzheimer Disease

Project description:MicroRNAs (miRNAs) could play an important role as potential Alzheimer Disease (AD) biomarkers. Plasma samples were collected from participants: Mild cognitive impairment (MCI) due to AD patients (n= 20), preclinical AD patients (n= 8) and healthy controls (n= 20). Then, small RNA sequencing analysis, followed by miRNA differential expression analysis comparing different methods (DESeq2, edgeR, NOISeq) were carried out.

2022-05-08 | E-MTAB-11103 | biostudies-arrayexpress

Targeting the Post-Synaptic Proteome in Alzheimer Disease with Psychosis

Project description:Individuals with Alzheimer Disease who develop psychotic symptoms (AD+P) experience more rapid cognitive decline and have reduced indices of synaptic integrity relative to those without psychosis (AD-P). We sought to determine whether the postsynaptic density (PSD) proteome is altered in AD+P relative to AD-P, analyzing PSDs from dorsolateral prefrontal cortex of AD+P, AD-P, and a reference group of cognitively normal elderly subjects. The PSD proteome of AD+P showed a global shift towards lower levels of all proteins relative to AD-P, enriched for kinases, proteins regulating Rho GTPases, and other regulators of the actin cytoskeleton. We computationally identified potential novel therapies predicted to reverse the PSD protein signature of AD+P. Five days of administration of one of these drugs, the C-C Motif Chemokine Receptor 5 inhibitor, maraviroc, led to a net reversal of the PSD protein signature in adult mice, nominating it as a novel potential treatment for AD+P.

2023-06-19 | PXD042025 | Pride

Transcription profiling of human peripheral blood mononuclear cells of dementia and Alzheimer patients

2009-12-04 | E-GEOD-18309 | biostudies-arrayexpress

Targeting the Post-Synaptic Proteome in Alzheimer Disease with Psychosis

Project description:Individuals with Alzheimer Disease with psychotic symptoms (AD+P) experience more rapid cognitive and functional decline, and have reduced indices of synaptic integrity, relative to those without psychosis (AD-P). We hypothesized the postsynaptic density (PSD) proteome is altered in AD+P relative to AD-P, and that this proteomic signature could be used to nominate novel pharmacotherapies. METHODS: Liquid-Chromatography/Mass Spectrometry analysis of PSDs from dorsolateral prefrontal cortex of AD+P, AD-P and cognitively normal elderly subjects. RESULTS: The PSD proteome signature of AD+P was characterized by lower levels of a network of kinases, proteins regulating Rho GTPases, and proteins regulating the actin cytoskeleton. Potential novel therapies identified included the C-C Motif Chemokine Receptor 5 inhibitor, maraviroc. DISCUSSION: AD+P is characterized by broad changes in the PSD proteome in prefrontal cortex. Further testing of potential therapies for their ability to reverse these changes and protect against psychotic-like behaviors in model systems is warranted.

2023-06-19 | PXD042026 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data